Introduction
Since the 1996 publication in Blood "Biological Basis for Interleukin-1 in Disease" 1 , there have been several major advances in understanding a role for IL-1 in the pathogenesis of disease. Because of its property as a hematopoietic factor, IL-1 was administered to patients in order to improve recovery following bone marrow transplantation (human responses to IL-1
were reviewed in detail in 1996). 1 Effective in reducing the duration of thrombocytopenia and leukopenia, recipients of IL-1 therapy experienced unacceptable signs and symptoms of systemic inflammation, including hypotension. Therefore, attention was initially focused on blocking IL-1 activity in sepsis using the naturally occurring IL-1 receptor antagonist (IL-1Ra), now known by its generic name anakinra. There were three controlled trials of anakinra in human sepsis. Although in each trial there was a reduction in 28-day all cause mortality compared to placebo-treated patients, the reductions did not reach statistical significance. 2 The failure of blocking IL-1 to significantly reduce mortality in septic shock is not unusual, as most anti-cytokines and anti-inflammatory agents have also failed in sepsis trials (reviewed in Eichacker). 3 Subsequently, attention focused on blocking IL-1 in non-infectious, chronic inflammatory conditions, such as rheumatoid arthritis. Anakinra is approved for reducing the signs and symptoms of rheumatoid arthritis and slows the progressive joint destructive characteristics of the disease. Anakinra has also been administered to patients with smoldering/indolent myeloma at high risk for progression to multiple myeloma. In combination with a weekly low dose of dexamethasone, anakinra treatment provided a significant increase in the number of years of progression free disease. 4 Consistently, there are no organ toxicities or gastrointestinal disturbances with anakinra or other parenteral therapies to reduce IL-1 activity.
Blocking IL-1, particularly IL-1β, is now the standard of therapy for a class of inflammatory syndromes termed "auto-inflammatory" diseases (reviewed by Kastner and Simon). 5, 6 Autoinflammatory syndromes are distinct from autoimmune diseases. In autoimmune diseases, the T-cell is associated with pathogenesis as the dysfunctional cell or "driver" of inflammation.
Immunosuppressive therapies targeting T-cell function as well as antibodies that deplete T and B cells are effective in treating autoimmune diseases. In contrast, in auto-inflammatory diseases, the monocyte-macrophage is the dysfunctional cell, which directly promotes
For personal use only. on July 15, 2017. by guest www.bloodjournal.org From inflammation. Auto-inflammatory conditions are characterized by recurrent bouts of fever with debilitating local and systemic inflammation; they are often responsive to IL-1β blockade (Table 1) . In general, these diseases are poorly controlled with immunosuppressive therapies and responses to blocking TNFα, if any, are modest. In this review, a growing number of unrelated diseases often responsive to blocking IL-1β are discussed.
From IL-1α and IL-1β to the IL-1 superfamily of ligands and receptors
Similarities in the IL-1 family. Although the original IL-1 family was comprised of only IL-1α and IL-1β, the IL-1 family has expanded considerably. As shown in Table 2 , there are eleven members. The IL-1 receptor family has also expanded to nine distinct genes and includes co-receptors, decoy receptors, binding proteins and inhibitory receptors. 7 In terms of human disease, the properties of IL-1 itself still remain the model for mediating inflammation.
As shown in Figure 1 , IL-1α or IL-1β bind first to the ligand binding chain, termed type I (IL-1RI). This is followed by recruitment of the co-receptor chain, termed the accessory protein Similarly, IL-18 first binds to its ligand binding chain, IL-18Rα, recruits its co-receptor the IL-18Rβ chain and a pro-inflammatory signal is initiated ( Figure 1 and Table 2 ). Family members IL-36α, β and γ (formerly termed IL-1F6, IL-1F8 and IL-1F9) bind to the IL-1Rp2, recruit the same IL-1RAcP and a pro-inflammatory signal is initiated. IL-36Ra (formerly IL-1F5) also binds to the IL-1Rp2, but does not recruit IL-1RAcP and acts as the natural occurring receptor antagonist for IL-36α, β and γ. IL-33 binds to ST2, also recruits the IL-1RAcP, but Th2-like properties characterize IL-33. Thus, the six pro-inflammatory members of the IL-1 family each recruit the IL-1RAcP co-receptor with the TIR domain and MyD88 docks to each. Dual function cytokines. IL-1α and IL-33 are "dual function" cytokines in that in addition to binding to their respective cell surface receptors, the intracellular precursor forms translocate to the nucleus and influence transcription.
9,10 IL-33 is a bona fide transcription factor and the IL-1α N-terminal amino acids contain a nuclear localization site (reviewed in 7 ).
In general, the nuclear function of IL-1α or IL-33 is transcription of proinflammatory genes.
For example, expression of the N-terminal amino acids of IL-1α stimulates IL-8 production in the presence of complete blockade of the IL-1RI on the cell surface. 10 IL-37, formerly IL-1F7, also translocates to the nucleus. 11 but in the case of IL-37, there is a net decrease in inflammation. 11, 12 As such, IL-37 is a unique ligand in the IL-1 family as it functions as an antiinflammatory cytokine (see below). Thus, the link of the Toll protein to IL-1 and to non-specific host defense against invading
IL-1 and
For personal use only. on July 15, 2017. by guest www.bloodjournal.org From microorganisms had already been made. In 1992, Charles Janeway replaced the term "nonspecific resistance to infection" with "innate immune response". Still later, the existence a mammalian cell surface receptor for microbial products was demonstrated and as reviewed by O'Neill, these receptors are now called Toll-like Receptors (TLR). All TLR contain share the TIR domain with the IL-1RI. 13 With the new term "innate immunity" came the term "acquired immunity" and the concept that innate immunity affects acquired immunity. However, looking back, IL-1 is the best example of the non-specific nature of an "innate" cytokine. That innate immunity affects acquired immunity had already been reported in 1979, with the demonstration that human IL-1β enhanced antigen-specific responses of murine T-cells. 16 Humans have eleven TLRs. 13 Each has a unique extracellular domain comprised of leucine rich repeats, which recognize a diverse number of bacterial products, nucleic acids and possibly some endogenous lipoproteins. Intracellularly, however, each TLR has a functional TIR domain as does the IL-1RI. Similar to IL-1 receptors, TLRs recruit the intracellular adaptor protein MyD88 to the TIR domain as the first step in signal transduction. The TIR domain is also present in two IL-1 family receptors that function to inhibit inflammation (see Figure 1 ): the single Ig IL-1 related receptor (SIGIRR) 17 and the newly discovered IL-1R accessory protein, IL-1RAcPb. 18 The TIR of these inhibitory receptors have amino acid substitutions, which alter charge distribution of the TIR domain and prevent the recruitment of MyD88. 18 Since deletion of the TIR domain from IL-1RI prevented IL-1 signaling 14 , the presence of a functional TIR domain in both IL-1 and Toll-like receptors suggested that microbial products such as endotoxin could be ligands for TLRs. However, it was not until 1998-99 that different groups reported microbial products as ligands for TLRs. The TIR domain is perhaps one of the most conserved sequences in both plants and animals. 13 The near ubiquitous presence of the TIR domain reveals an unexpected duplication in evolution. Receptor signaling by the IL-1 family as well as for a large number of bacterial products and viral nucleic acids depend on the same TIR domain and therefore, the inflammatory manifestations are similar. Limiting inflammation in the IL-1 family of cytokines and receptors.
Two receptor antagonists. As listed in Table 2 , IL-1Ra binds to IL-1RI and is specific for preventing the activity of IL-1α and IL-1β. As shown in Figure 1 , IL-36α, IL-36β and IL-36γ each bind to IL-1Rrp2, recruit IL-1RAcP and initiate a pro-inflammatory signal. For example, IL-36α inhibits the differentiation of adipocytes and induces insulin resistance.
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However, IL-36Ra also binds to IL-1Rrp2, but similar to IL-1Ra, does not recruit IL-1RAcP.
Therefore, IL-36Ra is the specific receptor antagonist for IL-1Rrp2 and prevents the activity of IL-36α, IL-36β and IL-36γ. 22 In the skin, overexpression of IL-36α produces an inflammatory phenotype similar to that of psoriasis and is antagonized by IL-36Ra. 27, 28 As shown in Figure 1 more severe responses to acute renal injury, which is due to a greater infiltration of myeloid cells into the renal parenchyma. 30 Using the same model of acute renal injury, caspase-1 deficient mice are protected, most likely due to decreased IL-18 activity rather than decreased IL-1 effects. 31 Thus SIGIRR may keep IL-18 activity in the kidney at bay. Like SIGIRR, IL-1RAcPb contains the amino acids differences in its TIR domain that likely reduce binding of MyD88. 18 In addition to an altered TIR domain, IL-1RAcPb has a carboxyl extension of 140 amino acids. Carboxyl extensions are also present in SIGIRR as well as two other members of the IL-1 receptor family, TIGIRR-1 and TIGIRR-2. TIGIRR-2 is associated with an X-linked cognitive deficiency, which is apparently independent of IL-1 functions. Little is known whether these C-terminal segments contribute to the inhibitory properties of these receptors.
IL-1RAcPb.

A compelling case for the importance of the naturally occurring IL-1 receptor antagonist.
Rabbits passively immunized against their own endogenous IL-1Ra exhibit a worsening of colitis 32 and mice deficient in IL-1Ra develop spontaneous diseases such as a destructive arthritis 33 , an arteritis 34 and a psoriatic-like skin eruption. Furthermore, mice deficient in endogenous IL-1Ra develop aggressive tumors following exposure to carcinogens. 35 These data support the concept that the concentrations of IL-1β versus IL-1Ra affect the severity of some diseases. The single nucleotide polymorphism (SNP) rs4251961 C allele is associated with lower circulating levels of IL-1Ra (reviewed in 36, 37 ) and is common in type 2 diabetes. 37 The same polymorphism is associated with reduced survival in patients with colon carcinoma compared to those with the wild-type allele. The concept of an imbalance between IL-1β and IL-1Ra gained considerable legitimacy with reports of infants born with non-functional IL-1Ra. 38, 39 Soon after birth, the affected infants exhibited impressive systemic and local
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The inflammation resembled infection with sepsis-like multiorgan failure, but all cultures were sterile. Treatment with anakinra was life-saving; the inflammation abated and the bone lesions disappeared. IL-17 was prominently expressed in cells from these patients (see below). These findings are an extreme example that without functional IL-1Ra, the activity of endogenous IL-1 is "unopposed" and IL-1-driven inflammation can run rampant.
One can conclude that low levels of IL-1β can induce inflammation but the presence of natural IL-1Ra is sufficient to limit the inflammation. IL-1Ra is found in the circulation of healthy subjects in the range of 100-300 ng/mL, whereas IL-1β is in the picogram per milliliter range and is not easily detectable by standard ELISA methods in the same individuals. In healthy humans, daily total constitutive production of IL-1β has been calculated at 6 ng; in patients with cryopyrin-associated periodic syndromes (CAPS), a rare auto-inflammatory diseases associated with increased IL-1β secretion, the calculated amount of IL-1β was 31 ng/day. 40 These low amounts are consistent with reports of increased release of IL-1β from blood monocytes of patients with auto-inflammatory diseases. The increase is usually five to ten-fold more than that from blood monocytes of healthy subjects. Clinical characteristics of systemic auto-inflammatory diseases. Systemic auto-inflammatory diseases are syndromes. 5, 6, 47 As listed in Table 1 , although many are rare, the clinical manifestations are common. Fever, neutrophila and elevated hepatic acute phase proteins are characteristically present with painful joint, myalgias and debilitating fatigue.
These manifestations are consistent with the responses observed in humans following administration of intravenous IL-1; fever, neutrophilia and elevated IL-6 and ACTH levels were observed at doses of IL-1α or IL-1β as low as 1-3 ng/kg.
1
CAPS patients can present with a spectrum of disease severity. In the mildest form, Familial Cold-induced Autoinflammatory Syndrome, the episodes are triggered by cold exposure. 44 A more severe form is Muckle-Wells Syndrome in which the inflammation is persistent and apparently not related to cold but associated with the development of hearing loss and amyloidosis. 48 The most severe form of CAPS is Neonatal-Onset Multisystem Inflammatory Disease, which in addition to systemic inflammation is also associated with joint deformities and developmental disabilities in early childhood. caspase-1 is present in an active state. 51 Caspase-1 is also constitutively active in highly metastatic human melanoma cells. 52 In general, the release of active IL-1β from blood monocytes is tightly controlled with less than 20% of the total IL-1β precursor being processed and released. Although the release of active IL-1β from blood monocytes of healthy subjects takes place over several hours, the process can be accelerated by increased levels of extracellular ATP, which triggers the P2X7 purinergic receptor (Figure 2 ).
53,54
Activation of caspase-1. As shown in Figure 2 , following ATP binding to the P2X7
receptor, there is a rapid exit of potassium from the cell and intracellular potassium falls. With inhibition of ATP binding or in cells deficient in the P2X7 receptor, the amount of secreted IL-1β is low or absent. 55 The fall in intracellular potassium is thought to bring about the oligomerization of a highly specialize group of intracellular proteins termed the "inflammasome", which convert procaspase-1 to an active enzyme. 56 Active caspase-1 then cleaves the IL-1β precursor in specialize secretory lysosomes or in the cytosol, followed by secretion of "mature" IL-1β (Figure 2 ). Blood monocytes from patients with auto-inflammatory syndromes release more processed IL-1β than cells for healthy subjects and thus likely accounts for the inflammation in these diseases. [40] [41] [42] [43] An increase in the secretion of active IL-1β is observed in monocytes from patients with a gain of function mutation in a gene originally called
Cold-Induced Auto-inflammatory Syndrome-1. 57 The mutations in this gene result in a single amino acid change in the intracellular protein named cryopyrin, since following the exposure to cold, the patients develop fever and other manifestations of systemic inflammation. Cryopyrin 57 and a historical perspective of this important discovery has been published. 7 In 2004, NLRP3 was reported to associate with procaspase-1 and other intracellular proteins to form complex, which was termed the "inflammasome". 56 As shown in Figure 2 , these components activate procaspase-1, resulting in active caspase-1 followed by the processing and secretion of active IL-1β. However, about half the patients with classic symptoms and biochemical markers of CAPS, FMF and other auto-inflammatory diseases do not have mutations and the basis for increased secretion of IL-1β remains unknown. As noted above, the increase in IL-1β secretion in monocytes from patients with auto-inflammatory diseases is modest compared to that of monocytes from healthy subjects. Despite severe systemic inflammation, only a five-fold more IL-1β is produced each day in patients with CAPS compared to healthy controls. 40 Secretion of IL-1β. As shown in Figure 2 , multiple mechanisms have been reported for the secretion of the processed mature IL-1β; these include the loss of membrane integrity, a requirement for phospholipase C and secretory lysosomes 53 , the shedding of plasma membrane microvesicles or multivesicular bodies containing exosomes. In general, the release of active IL-1β takes place before there is significant release of lactate dehydrogenase, although some report that the release of IL-1β parallels that of lactate dehydrogenase. Pyroptosis is a caspase-1-dependent mechanism for cell death with the release of IL-1β 58 and may account for the release of active IL-1β in ischemic disease.
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Since caspase-1 is present in an active form in freshly obtained blood monocytes from healthy subjects, 51 the rate-limiting step in the secretion of IL-1β is at the transcriptional and translational level. But in monocytes from patients with single amino acid mutation in NLRP3, the release of active IL-1β occurs without a requirement for a rapid fall in the level of intracellular potassium. 43 . Although often studied using endotoxin-induced synthesis of the IL-1β precursor, inflammation in auto-inflammatory diseases is sterile. Continued treatment with anakinra results in a progressive reduction in the secretion of IL-1β from monocytes compared to secretion before treatment. 42, 43 A reduction in steady-state caspase-1 gene expression also takes place. 42 Thus, IL-1 itself increases the synthesis of caspase-1 as well as its own IL-1β precursor 59 and may account for the auto-inflammation of these diseases.
Caspase-1 independent processing of the IL-1β precursor into an active cytokine.
In the arthritic joint and following blunt trauma, hypoxia, hemorrhage or exposure to irritants, there is a brisk myeloid response into the affected tissues dominated by neutrophils. Although IL-1β
often plays a pivotal role in these conditions, caspase-1 may not be required. For example, IL-1β is required for irritant-induced inflammation in muscle tissue, but is caspase-1 independent. 60 Similarly, cartilage destruction in joints 61 and urate crystal-induced inflammation 62 are also IL-1β-dependent, but caspase-1 independent. In many models of sterile inflammation, cell death and release of the IL-1β precursor from resident macrophages or infiltrating monocytes takes place. With the infiltrating neutrophils, there is also a role for neutrophil proteases. As shown in Figure 3 , these proteases include elastase, chymases, granzyme A, cathepsin G and proteinase-3. In particular, proteinase-3 cleaves the inactive IL-1β precursor close to the caspase-1 site resulting in active IL-1β. 60, 61 Moreover, inhibition of neutrophil proteases prevented urate crystal-induced peritonitis. 62 These findings question whether caspase-1 is responsible for IL-1β-dependent inflammation in patients with gout or any inflammatory proccess where there is a robust infiltration of neutrophils in the release of the IL-1β precursor into the extracellular space.
Role of reactive oxygen species on caspase-1-dependent secretion of IL-1β.
Inflammation and carcinogenesis are associated with the generation of reactive oxygen species (ROS) and ROS have been proposed to activate the caspase-1 inflammasome. 63 Since IL-1β appears to play a role in carcinogenesis 35 , it is an attractive hypothesis that ROS directly activates the inflammasome to induce release of IL-1β and trigger inflammation. However, in cells deficient in deficient in gp91phox ROS, levels are low and IL-1β levels are high and in cells deficient in super oxide dismutase-1, ROS levels are high but caspase-1 is suppressed and IL-1β levels are low. 64 Comparable to murine cells deficient in gp91phox, humans with chronic granulomatous disease (CGD) have a mutation in p47-phox, with defective NADPH activity and are unable to generate ROS. Blood monocytes from these patients release IL-1β following stimulation in vitro. 65, 66 Although the well-known inhibitor of ROS, diphenylene iodonium (DPI), reduces the secretion of IL-1β in all studies, DPI inhibits IL-1β and also TNFα gene expression rather than caspase-1 activity. 65 Thus, it appears that ROS may dampen the inflammasome and this may explain why CGD patients, who are unable to generate ROS, have increased inflammation with granulomatous lesions and a form of colitis indistinguishable from that found in Crohn's disease. It has also been shown that ROS induces intracellular NAC, a potent anti-oxidant, which facilitates the secretion of active IL-1β. 67 Although ROS generation from mitochondria may contribute to caspase-1 activation, there is the conundrum that regardless of the source of ROS, the concept is not supported by decades of failed placebo controlled anti-oxidant trials.
Role of IL-1α in ischemia-induced inflammation. Cells of mesenchymal origin
constitutively contain preformed IL-1α precursor, for example, keratinocytes, endothelial cells and epithelial cells of the lung, kidney and gastrointestinal tract. If released from its intracellular pool in healthy cells, the IL-1α precursor is inflammatory. Thus it was not unexpected that a robust inflammatory responses were observed when extracts of cellular contents from healthy tissues containing the IL-1α precursor upon injection into the peritoneal cavity of mice 68, 69 .
Importantly, inflammation was shown to be MyD88 and IL-1RI dependent but TLR independent. 68, 69 . Intracellular IL-1α is found diffusely distributed in the cytosol as well as in the nucleus where it associates with chromatin. 70 The N-terminal domain of the IL-1α
precursor contains a nuclear localization sequence, which actively participates in transcription 10, 71 and affects the senescence of cells.
As shown in Figure 4 , during the hypoxia of an ischemic event, there is loss of membrane integrity in dying cells with the release of intracellular contents, which include the IL-1α precursor. 70 Subsequently, resident tissue macrophages respond to IL-1α and produce IL-1β
( Figure 4) . Although ischemia-induced inflammation is often initiated by the IL-1α precursor, it rapidly becomes caspase-1 and IL-1β dependent. 72 Adenoviruses infection induces a neutrophil infiltration which is independent of TLR9 and NLRP3 73 and the inflammation is due to IL-1α activation of the IL-1RI with a brisk production of chemokines. 73 Cell death by a caspase-1-dependent process called pyroptosis may also take place in ischemic tissues with in the release of cell contents. 58 In contrast, the same mesenchymally-derived cells undergo apoptosis as part of normal tissue renewal. During apoptosis, intracellular IL-1α concentrates in dense nuclear foci and
For personal use only. on July 15, 2017. by guest www.bloodjournal.org From chromatin binding is not reversed by histone deacetylases or affected by inhibitors of reactive oxygen species. 70 As illustrated in Figure 4 , in apoptotic cells, IL-1α is retained within the chromatin fraction and is not present in the cytoplasmic contents. As such, lysates of cells undergoing apoptotic death are biologically inactive. 70 Thus, nuclear trafficking and differential release during necrosis versus apoptosis (Figure 4) demonstrates that inflammation by IL-1α is tightly controlled.
IL-1β, periodonditis and bone loss. Epidemiologic studies have examined
polymorphisms in the IL-1 gene cluster (IL-1α, IL-1β and IL-1Ra) with increased periodontitis and tooth loss as well as with coronary heart disease (CHD) and type 2 diabetes. In a study in Germany, over 1,500 subjects with increased levels of HbA1c were found to have significant periodontal disease compared to normoglycemic subjects. Diabetics with IL-1β promoter genotype C/T or T/T exhibited a more severe form of periodontitis compared to wild-type IL-1β counterparts suggesting that carrying these polymorphisms increases the inflammation. In another study, mean alveolar bone levels were measured in patients with CHD. The same polymorphisms were associated with bone loss. An IL-1Ra polymorphism was also associated with both CHD and the highest level of bone loss. In patients with the IL-1α +4845T
polymorphism, there was a statistically significant correlation with acute coronary syndrome and severe periodontitis.
The mechanism of IL-1β production in periodontitis has been extensively studied using bacteria isolated from patients with long-standing disease. The most persistent bacterial infection in periodontitis is A. actinomycetemcomitans, which infects the periodontal space in many throughout the world and is the most common cause of tooth loss. 74 These organisms produce a leukotoxin, which induces degranulation and lysis in human neutrophils. The leukotoxin also activates caspase-1 and the secretion of large amounts of IL-1β from human macrophages. 74 IL-1β is known a player in bone loss in patients with rheumatoid arthritis and the amino acid sequence of purified osteoclast activating factor is identical to that of IL-1β.
Thus, the induction of IL-1β in the periodontal space by the leukotoxin likely explains alveolar bone tooth loss with periodontitis. Since the inflammation in periodonitis appears to be IL-1β mediated, IL-1β entering the circulation from the local inflammation in the periodontal space
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IL-1 in B-and T-cell Responses
IL-1β as an adjuvant.
A role for IL-1β in antibody production has been repeatedly reported (reviewed in). 75 Not unexpectedly, the most widely used adjuvant, aluminum hydroxide (alum), induces IL-1β via a caspase-1 dependent mechanism. Previous studies revealed that mice deficient in IL-1β do not produce anti-sheep red blood cell antibodies, a Tdependent response. In wild-type mice, IL-1β causes a marked increase in the expansion of naive and memory CD4 T cells in response to antigen and particularly when used with LPS as a co-stimulant. 76 In fact, when LPS is used as an adjuvant approximately 55% of the antibody response is due to IL-1. 76 There are also striking increases in serum IgE and IgG1 levels. The role of IL-1β in the generation of Th17 cells is also consistent with the inflammation in mice deficient in IL-1Ra. 80 In mice deficient in IL-1Ra, the activity of endogenous IL-1 is unopposed and spontaneous rheumatoid arthritis-like disease develops 33 , but not in mice also deficient in IL-17. 81 In mice specifically deficient in endogenous IL-1Ra in myeloid cells, collagen-induced arthritis appears to be due to unopposed IL-1 activity, which drives IL-17. 82 IL-1-dependent IL-17 production may be relevant to EAE, the rodent model for multiple
For personal use only. on July 15, 2017. by guest www.bloodjournal.org From sclerosis. Mice deficient in both IL-1α and IL-1β do not develop EAE, which is thought to be a failure to mount a Th17 response. In mice deficient in caspase-1, EAE is markedly attenuated.
Thus, IL-1 rather than TNFα blockade reduces disease severity in mice subjected to EAE; in fact, blocking TNFα worsens the outcome of the EAE model. In rheumatoid arthritis, depleting CD20 bearing B-cells results in decreased IL-17 production, 83 which may be due to a reduction in B-cell IL-1β.
Although there is no dearth of reports that adding IL-1 to cultures induces IL-17, an essential role for IL-1 was shown when mice deficient in the IL-1R fail to induce IL-17 upon antigen challenge. 84 Moreover, IL-23 fails to sustain IL-17 in IL-1R deficient T-cells and
TNFα and IL-6 enhancement of IL-23-induced IL-17 is also IL-1 dependent. 84 In a subsequent study of EAE, γ/δ CD4 positive T-cells were the source of IL-17 but independent of T-cell receptor engagement. γ/δ CD4 positive T-cells contain the RORγ transcription factor and thus a direct induction of IL-17 by IL-1 is fundamental to the Th17 paradigm. Therefore, it is likely that there is a cascade of IL-1β-induced IL-23 as well as IL-1-induced IL-6 for Th17 differentiation.
In human T-cells, IL-1β dependent Th17 differentiation is due to the intermediate production of PGE2 from macrophages. 85 This observation is consistent with ability of IL-1β to induce COX-2 (reviewed in) 7 and PGE2 to induce IL-6. Thus, an innate inflammatory response that is IL-1β-driven appears to play a pivotal role in the outcome of EAE. In order to maintain Th1-driven responses, IFNγ suppresses the differentiation into the Th17 phenotype. One possible mechanism by which IFNγ suppresses Th17 is via the suppression of IL-1. IFNγ reduces the induction of IL-1 by IL-1 and also of IL-1-induced PGE2 (reviewed in Dinarello). 1 Thus, IFNγ suppression of IL-1-driven PGE2 as well as IL-1 itself may explain the reduction in Th17 differentiation.
Blocking IL-1β-mediated Disease
Therapeutic agents. Intitially, anakinra was used to treat several unrelated chronic inflammatory diseases as listed in Table 1 . Today, these diseases are also successfully treated with neutralization by human anti-IL-1β monoclonal antibodies. For example in type 2 diabetes, either anakinra or monoclonal antibodies to IL-1β improve glycemic control. 37, 86, 87 For personal use only. on July 15, 2017. by guest www.bloodjournal.org From months of anakinra monotherapy resulted in progression-free disease greater than 3 years compared to 6 months in patients with less than a 15% fall during anakinra therapy (p<0.002).
Thus, an effective reduction in IL-1β activity using CRP as the marker for IL-1β-induced IL-6 halts progression to active myeloma. With the use of anakinra in over 200,000 patients with rheumatoid arthritis or auto-inflammatory diseases, no opportunistic infections, including Mycobacterium tuberculosis reactivation, have been reported.
Angiogenesis. Angiogenesis plays a pathological role in multiple myeloma. In vitro and in animal models, there are a growing number of reports on IL-1β as a key cytokine in angiogenesis. [88] [89] [90] Compared to thalidomide or its analogues, blocking IL-1β is essentially free of toxic side effects. There is an ongoing NIH trial of anakinra as an anti-angiogenic therapy in patients with cutaneous melanoma. Because blocking IL-1β reduces IL-6 as well as the proangiogenic chemokine IL-8, the use of IL-1β blocking strategies may result in therapy in high risk patients with smoldering/indolent myeloma or metastatic melanoma. There is also a role for IL-1β in the angiogenic process of macula degeneration 91 and anakinra treatment in rheumatoid arthritis reduces the vascularization of the pannus. controlled trial, patients were treated with anakinra four days prior to and ten days following allogeneic stem cell transplantation added to standards of therapy. Moderate to severe GvHD developed in both anakinra and placebo-treated patients. 92 One can conclude that during conditioning and 10 days after transplantation, IL-1 plays no significant role in the development of the disease. In contrast, in patients with full-blown GvHD, blocking IL-1 reduced the severity of the disease. 93 Using a continuous intravenous infusion of anakinra, there was improvement in the clinical score in 16 of 17 treated patients. Moreover, a decrease in the steady state mRNA for TNF-α in peripheral blood mononuclear cells correlated with improvement (p=0.001). 93 It is likely that there is role for IL-1 in the inflammatory manifestations of GvHD rather than the immunological development of the disease. [96] [97] [98] The effect of IL-1 blockade appears to be superior to that of steroids and result in prolonged periods without flares. Although some studies report that urate crystals directly activate the NLRP3 for processing of the IL-1β precursor 99 , it is likely that two signals are required; urate crystals plus free fatty acids account for IL-1β activity in flares of gout. 100, 101 Given the characteristic neutrophilic infiltration in gouty joints, it is also likely that the IL-1β precursor is processed extracellularly by neutrophilic enzymes as shown in Figure 3 .
Effects of IL-1 receptor blockade in stroke.
Although infection, particularly septic shock, evokes a "cytokine storm" as part of a systemic inflammatory response, in many ischemic diseases such as acute lung injury, thrombotic stroke, acute renal failure, myocardial infarction and hepatic failure, inflammation is characterized by cell death and infiltration of neutrophils into the ischemic area. The induction of IL-1β in human monocytes exposed to hypoxia was first reported in 1991. 102 Subsequently, many studies have demonstrated an essential role for IL-1 and specifically for IL-1β and caspase-1 in various models of ischemic injury without and with reperfusion. A randomized, double blind, placebo controlled trial of anakinra was carriedout in patients with acute stroke. Three days of a high dose of intravenous anakinra was administered, the same dose used in the sepsis trials. 103 Peripheral white blood cells, neutrophil counts, CRP and IL-6 concentrations were lower in anakinra treated compared to placebotreated patients. After 3 months, the anakinra-treated patients exhibited less loss of cognitive function compared to the placebo group.
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Reducing IL-1β in type-2 diabetes. For over 25 years, the cytotoxic effects of IL-1β for the insulin-producing pancreatic beta cell have been studied. 104 Subsequently, it was shown that high concentrations of glucose stimulated IL-1β production from the beta-cell itself 105 implicating a role for IL-1β in type 2 diabetes. 106 In addition, free fatty acids act together with glucose to stimulate IL-1β from the beta cell. The production of IL-1β also increases to the deposition of amyloid via activation of NLRP3. 107 In support of these studies, gene expression for IL-1β was over one hundred-fold higher in beta cells from type 2 patients compared to nondiabetic patients. The clinical proof of a role for IL-1β in the pathogenesis of type 2 diabetes came from a randomized, placebo controlled study of anakinra for 13 weeks, in which improved insulin production and glycemic control associated with decreased CRP and IL-6 levels was reported. 86 In the 39 weeks following the 13 week course of anakinra, patients who responded to anakinra used 66% less insulin to obtain the same glycemic control compared to baseline requirements. 37 This observation suggests that blocking IL-1β even for a short period of time restores the function of the beta cells or possibly allows for partial regeneration of beta cells.
Several trials blocking TNFα in type-2 diabetes have succeeded in reducing CRP but did not improve glycemic control. The findings of anakinra therapy in type 2 diabetic patients have been confirmed using canakinumab as well as another neutralizing monoclonal antibody to IL-1β 87 The data also provides evidence that short-term blockade of IL-1β restores the function of the beta cells or possibly regeneration.
The above studies are consistent with the concept that type-2 diabetes is a chronic IL-1-mediated disease and could be classified as an auto-inflammatory disease in which IL-1β-mediated inflammation progressively destroys the insulin-producing beta cells. The IL-1β can come from the beta-cell itself, from infiltrating macrophages into the islet or from the adipose tissue stores. A requirement for caspase-1 in regulating IL-1β production from the insulinproducing beta cell as well as the adipocyte provides a molecular mechanism. Differentiation of the adipocyte is caspase-1 dependent. 108 In diabetic mice, administration of a caspase-1 inhibitor reduces insulin resistance; in mice deficient in caspase-1, there is improved sensitivity to insulin. 108 Because type 2 diabetes increases risk of cardiovascular events, blocking IL-1β activity in these patients may also reduce the incidence in myocardial infarction and stroke as reviewed in Dinarello.
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IL-1β as a mediator of cartilage destruction in osteoarthritis. In the joint, IL-1β is the mediator of reduced chondrocyte proteoglycan synthesis, increased synthesis of matrix metalloproteinases and the release of nitric oxide. 109 Mice deficient in IL-1β are protected from inflammation-induced arthritis. The role of IL-1β in the destructive processes of osteoarthritis has also been studied in rabbits, pigs, dogs and horses. In a placebo-controlled trial of intraarticular anakinra in patients with knee osteoarthritis, there was a clear dose-dependent (50 mg versus 150 mg) reduction in pain and stiffness scores, but the benefit did not extend beyond one month. 110 The modest reduction may be due to the heterogeneity of the osteoarthritis population in general but also to the short duration of IL-1RI blockade by anakinra.
Does IL-1 contribute to heart failure after myocardial infarction? ST elevation myocardial infarction (STEMI) has a high risk of death but patients who survive the acute event progress to chronic heart failure due to loss of viable myocardium. In a randomized, placebocontrolled trial of patients with ST elevation myocardial infarction, daily anakinra was added to standard of therapy the day after angioplasty and continued for 14 days. Serial imaging and echocardiographic studies were performed over the following 10-14 weeks. 111 Left ventricular remodeling was significantly reduced with anakinra treatment and consistent with the reductions in CRP compared to patients receiving 14 days of placebo. After 18 months, 60% of placebo-treated patients had developed stage IV heart failure whereas there were none in the anakinra treated patients. These findings are consistent with experimental myocardial infarction in mice where blocking IL-1β results is a reduction in post-infarction remodeling. 72 It remains to be tested whether chronic heart failure in non-post myocardial infarction patients is reduced by IL-1β blockade. (either precursor or mature) or mature IL-1β bind to the IL-1RI and with the IL-1RAcP forms the receptor heterodimeric complex. The TIR domain of each receptor chain approximate, recruit MyD88, followed by phosphorylation of IRAKs and IKKβ resulting in a signal to the nucleus. Details on IL-1 signal transduction have been reviewed. 8 B. In the brain and spinal cord, the variant IL-1RAcPb can form the heterodimeric complex with IL-1α or IL-1β and IL-1RI, but this complex fails to recruit MyD88 and there is inhibition of the IL-1 signal. The failure to recruit MyD88 may be due to an altered TIR domain (indicated as TIRb). C. IL-1Ra binds to IL-1RI but there is no signal since there is failure to form a complex with IL-1RAcP. D. IL-1β binds to the IL-1RII, but lacking a cytoplasmic segment, there is no signal. E. Due to an altered TIR domain (indicated as TIRb), SIGIRR inhibits IL-1 and TLR signaling. SIGIRR can form a complex with IL-33 (not shown) and inhibit IL-33 signaling.
29 F. IL-1Rrp2 binds IL-36α, IL-36β or IL-36γ and forms a complex with IL-1RAcP. The TIR domain of each receptor chain approximates and recruits MyD88 similar to that shown in A. G. IL-36 Receptor antagonist (IL-36Rα) binds to IL-1Rrp2 but fails to form a complex with IL-1R AcP. Thus, IL-36Ra prevents the binding of IL-36α, IL-36β or IL-36γ to IL-1Rrp2 and IL-36Ra is the natural receptor antagonist IL-36. 
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